Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia

References

• Smith CC, Shah NP. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol Educ Program 2011;2011:121-7
   PubMed Web of Science ®Google Scholar
• Gleevec [package insert]. Novartis Pharmaceuticals Corp., East Hanover, NJ, USA. January 2015. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf [Last accessed 19 October 2015]
   Google Scholar
• Sprycel [package insert]. Bristol-Myers Squibb Co., Princeton, NJ, USA. August 2015. Available at: http://packageinserts.bms.com/pi/pi_sprycel.pdf [Last accessed 19 October 2015]
   Google Scholar
• Tasigna [package insert]. Novartis Pharmaceuticals Corp., East Hanover, NJ, USA. October 2015. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf [Last accessed 19 October 2015]
   Google Scholar
• Bosulif [package insert]. Pfizer Inc., NY, NY, USA. September 2015. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=884 [Last accessed 19 October 2015]
   Google Scholar
• Iclusig [package insert]. ARIAD Pharmaceuticals Inc., Cambridge, MA, USA. September 2014. Available at: http://iclusig.com/hcp/wp-content/uploads/2014/10/October-2014-Iclusig-Prescribing-Information.pdf [Last accessed 19 October 2015]
   Google Scholar
• Santos FP, Kantarjian H, Quintás-Cardama A, Cortes J. Evolution of therapies for chronic myelogenous leukemia. Cancer J 2011;17:465-76
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer 2011;117:897-906
   PubMed Web of Science ®Google Scholar
• Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk 2013;13:515-29
   PubMed Web of Science ®Google Scholar
• Haznedaroglu IC. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations. Expert Opin Pharmacother 2013;14:2005-10
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011;118:4554-60
   PubMed Web of Science ®Google Scholar
• Phillips KM, Pinilla-Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 2013;21:1097-103
   PubMed Web of Science ®Google Scholar
• Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-42
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841-51
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141-5
   PubMed Web of Science ®Google Scholar
• Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232-40
   PubMed Web of Science ®Google Scholar
• Giles FJ, Abruzzese E, Rosti G, et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 2010;24:1299-301
   PubMed Web of Science ®Google Scholar
• Garg RJ, Kantarjian H, O’Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009;114:4361-8
   PubMed Web of Science ®Google Scholar
• Iyer S, Trask PC, Siu G, Mardekian J. Health care resource utilization and cost in patients with chronic myeloid leukemia in a privately insured patient population in the United States. Blood (ASH Annual Meeting Abstracts) 2011;118:Abstract 4220
   Google Scholar
• Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010;26:61-9
   PubMed Web of Science ®Google Scholar
• Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25:481-96
   PubMed Web of Science ®Google Scholar
• Wu EQ, Guerin A, Yu AP, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010;26:2861-9
   PubMed Web of Science ®Google Scholar
• Ward MA, Fang G, Richards KL, et al. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Curr Med Res Opin 2015;31:289-97
   PubMed Web of Science ®Google Scholar
• Knopf KB, Divino V, McGarry L, et al. Economic burden of tyrosine kinase inhibitor treatment failure in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 2015; 15(11):e163-71. doi: 10.1016/j.clml.2015.07.647.Epub 2015 Aug 5
   PubMedGoogle Scholar
• Teitelbaum A, Ba-Mancini A, Huang H, Henk HJ. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist 2013;18:37-45
   PubMed Web of Science ®Google Scholar
• Trivedi D, Landsman-Blumberg P, Darkow T, et al. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. J Manag Care Spec Pharm 2014;20:1006-15
   PubMed Web of Science ®Google Scholar
• Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014;32:306-11
   PubMed Web of Science ®Google Scholar
• US Bureau of Labor Statistics. Consumer Price Indexes (CPI) Program. Available at: http://www.bls.gov/cpi/ [Last accessed 5 March 2014]
   Google Scholar
• Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics 2005;6:93-109
   PubMed Web of Science ®Google Scholar
• Darkow T, Maclean JR, Joyce GF, et al. Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia. Am J Manag Care 2012;18:S272-8
   Google Scholar